have identified the immunogenic LDHC-derived peptides P11 (LDHC41–55) and P73 (LDHC288–303) that elicited CD8+ T-cell responses against HLA-A*0201/LDHC-positive breast cancer cells, demonstrating increased IFN-γ secretion and cytolytic activity (13). Here, HLA-A is linked to breast carcinoma.